Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.
Please see terms and conditions for restrictions on use of Citywire's Fund Manager database.

This Fund Manager Rating is based on the Citywire Long Only ratings methodology

Citywire Ratings are rewarded for risk adjusted outperformance of benchmarks we select independently More information on how Ratings are calculated

Rudi Van den Eynde

Rudi Van den Eynde

Showing manager performance in Switzerland View performance globally

Citywire Rating: A rated

2013

  • SNot rated in Sep 2013
  • ONot rated in Oct 2013
  • NNot rated in Nov 2013
  • DNot rated in Dec 2013

2014

  • JNot rated in Jan 2014
  • FNot rated in Feb 2014
  • MNot rated in Mar 2014
  • ANot rated in Apr 2014
  • MNot rated in May 2014
  • JNot rated in Jun 2014
  • JNot rated in Jul 2014
  • ANot rated in Aug 2014
  • SNot rated in Sep 2014
  • ONot rated in Oct 2014
  • NRated A in Nov 2014
  • DRated A in Dec 2014

2015

  • JRated A in Jan 2015
  • FRated A in Feb 2015
  • MRated A in Mar 2015
  • ARated A in Apr 2015
  • MRated A in May 2015
  • JRated A in Jun 2015
  • JRated A in Jul 2015
  • ARated A in Aug 2015
  • SRated A in Sep 2015
  • ORated A in Oct 2015
  • NRated A in Nov 2015
  • DRated A in Dec 2015

2016

  • JRated A in Jan 2016
  • FNot rated in Feb 2016
  • MNot rated in Mar 2016
  • ANot rated in Apr 2016
  • MNot rated in May 2016
  • JNot rated in Jun 2016
  • JNot rated in Jul 2016
  • ANot rated in Aug 2016
  • SNot rated in Sep 2016
  • ONot rated in Oct 2016
  • NNot rated in Nov 2016
  • DNot rated in Dec 2016

2017

  • JNot rated in Jan 2017
  • FNot rated in Feb 2017
  • MNot rated in Mar 2017
  • ANot rated in Apr 2017
  • MRated Plus in May 2017
  • JRated Plus in Jun 2017
  • JRated Plus in Jul 2017
  • ARated A in Aug 2017
  • SRated A in Sep 2017

Performance

Equity - Biotechnology
over : 31/08/2016 - 31/08/2017

Total Return

Month by Month Performance

Quarterly Performance

to 30/06/2017 Annual Q1 Q2 Q3 Q4
2017 11.1% 2.6%
2016 -18.3% -27.4% 2.0% 13.7% -3.0%
2015 8.9% 8.7% 1.8% -14.1% 14.6%
2014 51.4% 3.9% 7.8% 14.5% 18.0%
2013 59.8% 23.9% 6.5% 17.1% 3.5%
2012 -5.4%

Related News

Healthcare industry fighting fit after Trump win

From pricing pressures to Obamacare overhauls, leading managers reveal what the election impact for healthcare could be.

Pfizer to snap up Allergan: star managers clash over major deal

Leading sector specialists offer divided views on the benefits of the $160bn merger, which marks the biggest tie-up in the sector's history.

Biotech equity’s most consistent managers of the past five years

Citywire Global uncovers the pair of sector specialists continually staying ahead of the average peer over the past half-decade.

Part-time players could derail biotech boom, warns healthcare star

Citywire A-rated specialist Rudi Van Den Eynde believes over-exposure from generalist investors could hurt the sector.

Healthcare star: biotech’s M&A boom shows no sign of slowing

Citywire A-rated Rudi Van Den Eynde says although activity is in ‘full swing’ it is time position for more pick-ups.

Bright lights in biotech: two most consistent managers revealed

The specialist health care sector has received increased interest over the past five years but only two managers have regularly beaten the average manager.

Citywire Discovery Source: Citywire Discovery Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated)..Portions of the information contained on this page was derived by Citywire Financial Publishers Ltd using content supplied by Lipper, A Reuters Company.